title: Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters.
abstract: OBJECTIVE
  Survivin and cortactin are factors that promote tumor progression. We tested the hypothesis that survivin and cortactin expressions correlate with the clinico-pathological parameters of colorectal adenocarcinomas and survival time.
  
  
  METHODS
  Immunohistochemical analysis of survivin and cortactin were performed using tissue microarrays of 119 specimens from 18 well, 50 moderately, and 27 poorly differentiated colorectal adenocarcinomas and 24 colorectal adenomas with dysplasia. As control, 10 specimens of normal colorectal epithelia were included.
  
  
  RESULTS
  The percentage of cells immunostained and the immunostaining scores for survivin and cortactin were all significantly higher in well-, moderately, and poorly differentiated colorectal adenocarcinomas than in normal colorectal epithelia. The survivin immunostaining score was significantly correlated with T, M, and AJCC/TNM stages (p < 0.05). For cortactin, the score was significantly correlated with T and M stages (p < 0.05). Higher survivin immunostaining score was associated with higher mortality.
  
  
  CONCLUSIONS
  Higher expression of survivin and cortactin correlates significantly with tumor stages and shorter survival time. Survivin and cortactin may be good biomarkers of aggressiveness of colorectal adenocarcinomas. Our findings require validation in independent cohorts and these data support the potential targeting of survivin and cortactin for the development of novel therapeutic strategies.
authors.affiliation: Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
authors.forename: Ying-Yu
authors.initials: YY
authors.lastname: Lee
authors.forename: Cheng-Ping
authors.initials: CP
authors.lastname: Yu
authors.forename: Chih-Kung
authors.initials: CK
authors.lastname: Lin
authors.forename: Shin
authors.initials: S
authors.lastname: Nieh
authors.forename: Kuo-Feng
authors.initials: KF
authors.lastname: Hsu
authors.forename: Hung
authors.initials: H
authors.lastname: Chiang
authors.forename: Jong-Shiaw
authors.initials: JS
authors.lastname: Jin
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000556:secondary; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D051356:Cortactin / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D009367:Neoplasm Staging; D015996:Survival Rate; D000077022:Survivin; D046888:Tissue Array Analysis
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; C495868:CTTN protein, human; D051356:Cortactin; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D000077022:Survivin